TrialsgrambetaRCTs are beautiful

2024 ESC Guidelines for the management of elevated blood pressure and hypertension

This guideline cites 7 of the 199 landmark trials in our Cardiology register.

The 2024 ESC Guidelines introduce an 'elevated blood pressure' category and a general systolic target of 120–129 mmHg, spanning measurement, drug therapy, device treatment and cardiovascular prevention. This page maps the landmark trials from our register that the guideline cites — grouped by theme.

Blood-pressure targets & intensive lowering2

  • 2015SPRINT Core⁠Cardiology · HTN · BP targetIn 9,361 high-risk non-diabetic hypertensive adults, intensive BP control to SBP < 120 mm Hg reduced CV events and all-cause mortality compared with standard control to SBP < 140 mm Hg.HR 0.75Read →
  • 2008HYVET⁠Cardiology · HTN · ElderlyIn 3,845 patients with hypertension aged 80 or older, antihypertensive treatment reduced stroke and all-cause mortality compared with placebo.Read →

Drug therapy & combinations2

  • 2015PATHWAY-2⁠Cardiology · HTN · MRAIn 335 patients with drug-resistant hypertension, add-on spironolactone lowered home systolic blood pressure more than placebo, bisoprolol, or doxazosin.Read →
  • 2002ALLHAT⁠Cardiology · HTN · Drug classIn 33,357 hypertensive patients ≥ 55 with ≥ 1 CV risk factor, chlorthalidone was at least as effective as amlodipine or lisinopril for preventing fatal CHD or non-fatal MI.Read →

Renal denervation (device therapy)2

  • 2023SPYRAL HTN-ON MED⁠Cardiology · HTN · Renal denervationIn 337 patients with uncontrolled hypertension on 1-3 antihypertensive drugs, radiofrequency renal denervation did not significantly lower 24-hour ambulatory systolic blood pressure at 6 months versus a sham procedure (-1.9 mmHg, 95% CI -4.4 to 0.5).Read →
  • 2014SYMPLICITY HTN-3⁠Cardiology · HTN · Renal denervationIn 535 patients with resistant hypertension, catheter-based renal denervation did not lower office systolic blood pressure compared with a sham procedure.Read →

Cardiovascular prevention1

  • 2000HOPE⁠Cardiology · Coronary · ACE inhibitorIn 9,297 high-risk patients with vascular disease or diabetes and preserved LV function, ramipril reduced MI, stroke, or cardiovascular death compared with placebo.RR 0.7895% CI 0.70-0.86Read →

Cited landmark trials not yet in the register6

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2021STEP

    Intensive BP lowering in older Chinese patients (distinct from register trial STEP 1, a semaglutide study).

  • 2024ESPRIT

    Systolic target below 120 mmHg.

  • 2019SPRINT MIND

    Intensive BP lowering and dementia risk.

  • 2010ACCORD BP

    Blood-pressure target in type 2 diabetes.

  • 2008ONTARGET

    No benefit from combined ACE inhibitor + ARB.

  • 2021RADIANCE-HTN

    Ultrasound renal denervation (alongside register trial SPYRAL HTN-ON MED).

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.